Empagliflozin plus olanzapine to reduce metabolic side effects
Treatments studied
Part of Hormones & metabolism, Mental health clinical trials.
This trial tests whether adding empagliflozin to standard olanzapine treatment can improve metabolic problems (like blood sugar and cholesterol changes) that can happen with olanzapine in people with schizophrenia. If you qualify, you would be closely monitored for benefits and side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 60 years old and have schizophrenia
- Currently take olanzapine (the main schizophrenia medicine)
- Need to be willing to add empagliflozin as part of the study (if randomized)
- Have no other inflammatory or major related conditions that would make participation unsafe
- Follow study visits and monitoring as required
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if empagliflozin, a diabetes medicine, can improve weight and metabolism in people with HIV who take dolutegravir and have a high body mass index (BMI). It may help reduce weight gain linked to HIV treatment.
This trial tests if empagliflozin, a medication typically used for diabetes, can help people with metabolic syndrome (a cluster of conditions like large waist size, high blood sugar, and high blood pressure). It may improve health and reduce the risk of heart disease.
This trial tests a new combination tablet (olanzapine-samidorphan) for adults with schizophrenia. It aims to see if it helps control symptoms while potentially reducing weight gain, which can be a side effect of some schizophrenia medicines.
This trial tests if empagliflozin (a diabetes drug) can help improve depression symptoms in people with bipolar disorder who also have insulin resistance. You take it alongside your current bipolar medications.
This trial studies whether empagliflozin, a blood-sugar–related medicine, can safely improve chronic low blood sodium when you are not too “dry” or have an imbalanced fluid state. It may help stabilize sodium levels and related health symptoms, but you must meet specific blood and organ-function criteria.
This Phase 2 trial tests whether an SGLT2 medicine (like empagliflozin) can reduce symptoms of major depression. It may help people with moderate-to-severe depression who are otherwise eligible for the study.
Hear when a new Sodium-glucose Transport Protein Two Inhibitor (SGLT2),Metabolic Deficits Caused by Antipsychotics trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.